Its marketed products include EYLEA, Dupixent, Libtayo, Kevzara, and others. On March 14, Evan Seigerman, an analyst from BMO Capital, maintained a Buy rating on the stock with a price target of $903.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands eighth among the most promising stocks according to Wall Street analysts. The company is focused on developing life-changing medicines for ...
From foodservice and retail to packaging and equipment, discover the latest seafood products available to support your business or offer to your end customer with the SeafoodSource Product Showcase.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback